Claims
- 1. A method for inhibiting angiogenesis, comprising administering to an animal a biologically effective amount of a pharmaceutically acceptable CXC chemokine composition that comprises a non-ELR CXC chemokine other than PF4, the non-ELR CXC chemokine lacking the amino acid sequence ELR (Glu Leu Arg).
- 2. The method of claim 1, wherein said CXC chemokine composition comprises IP-10.
- 3. The method of claim 1, wherein said CXC chemokine composition comprises MIG.
- 4. The method of claim 1, wherein said CXC chemokine composition comprises an ELR-CXC chemokine modified to remove or replace the amino acid sequence ELR.
- 5. The method of claim 4, wherein said CXC chemokine composition comprises an ELR-CXC chemokine in which the amino acid sequence ELR has been replaced with the amino acid sequence TVR.
- 6. The method of claim 4, wherein said CXC chemokine composition comprises an ELR-CXC chemokine in which the amino acid sequence ELR has been replaced with the amino acid sequence DLQ.
- 7. The method of claim 4, wherein said CXC chemokine composition comprises an ELR-CXC chemokine in which the amino acid sequence ELR has been replaced with the amino acid sequence KGR.
- 8. The method of claim 4, wherein said CXC chemokine composition comprises an IL-8 polypeptide modified to remove or replace the amino acid sequence ELR.
- 9. The method of claim 8, wherein said CXC chemokine composition comprises an IL-8 polypeptide in which the amino acid sequence ELR has been replaced with the amino acid sequence TVR.
- 10. The method of claim 8, wherein said CXC chemokine composition comprises an IL-8 polypeptide in which the amino acid sequence ELR has been replaced with the amino acid sequence DLQ.
- 11. The method of claim 8, wherein said CXC chemokine composition comprises an IL-8 polypeptide in which the amino acid sequence ELR has been replaced with the amino acid sequence KGR.
- 12. The method of claim 1, wherein said CXC chemokine composition comprises a non-ELR CXC chemokine prepared by expressing a CXC chemokine gene in a recombinant host cell and collecting the expressed CXC chemokine protein.
- 13. The method of claim 1, wherein said CXC chemokine composition comprises a non-ELR CXC chemokine prepared by automated peptide synthesis.
- 14. The method of claim 1, wherein two non-ELR CXC chemokines are administered to said animal.
- 15. The method of claim 1, wherein said CXC chemokine composition is administered to said animal parenterally.
- 16. The method of claim 1, wherein said animal has a tumor.
- 17. The method of claim 1, wherein said animal is a human subject.
- 18. A method for inducing angiostasis, comprising administering to an animal a biologically effective amount of a pharmaceutically acceptable CXC chemokine composition that comprises a non-ELR CXC chemokine other than PF4, the non-ELR CXC chemokine lacking the amino acid sequence ELR.
- 19. The method of claim 18, wherein said CXC chemokine composition comprises IP-10.
- 20. The method of claim 18, wherein said CXC chemokine composition comprises MIG.
- 21. The method of claim 18, wherein said CXC chemokine composition comprises an ELR-CXC chemokine modified to remove or replace the amino acid sequence ELR.
- 22. The method of claim 18, wherein two non-ELR CXC chemokines are administered to said animal.
- 23. The method of claim 18, wherein said CXC chemokine composition is administered to said animal parenterally.
- 24. The method of claim 18, wherein said animal has a tumor.
- 25. The method of claim 18, wherein said animal is a human subject.
- 26. A method for inhibiting angiogenesis, comprising administering to an animal a pharmaceutically acceptable composition comprising a biologically effective amount of IP-10, MIG or an ELR-CXC chemokine modified to remove or replace the amino acid sequence ELR.
- 27. A method for inhibiting angiogenesis, comprising administering to an animal a pharmaceutically acceptable composition comprising a biologically effective amount of IP-10 or MIG.
- 28. A method for inducing angiostasis, comprising administering to an animal a pharmaceutically acceptable composition comprising a biologically effective amount of IP-10, MIG or an ELR-CXC chemokine modified to remove or replace the amino acid sequence ELR.
- 29. A method for inducing angiostasis, comprising administering to an animal a pharmaceutically acceptable composition comprising a biologically effective amount of IP-10 or MIG.
Government Interests
The U.S. Government owns rights in the present invention pursuant to grant numbers HL50057, HL39926 and HL31693 from the National Institutes of Health.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5459128 |
Rollins et al. |
Oct 1995 |
|
5739103 |
Rollins et al. |
Apr 1998 |
|